Literature DB >> 12958068

Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.

Tatjana Stankovic1, Mike Hubank, Debbie Cronin, Grant S Stewart, Danielle Fletcher, Colin R Bignell, Azra J Alvi, Belinda Austen, Victoria J Weston, Christopher Fegan, Philip J Byrd, Paul A H Moss, A Malcolm R Taylor.   

Abstract

The ATM/p53-dependent DNA damage response pathway plays an important role in the progression of lymphoid tumors. Inactivation of the ATM or TP53 gene is frequent in B-cell lymphocytic leukemia (B-CLL) and leads to aggressive disease. Although the ATM and p53 pathways overlap, they are not congruent, and it is unclear how the mechanism of tumor progression differs between ATM- and p53-deficient tumors. Using microarray analysis of ATM-mutant, TP53-mutant, and ATM/TP53 wild-type B-CLLs, we show that after exposure to DNA damage transcriptional responses are entirely dependent on ATM function. The p53 proapoptotic responses comprise only a part of ATM-regulated transcription; additionally, ATM regulates prosurvival responses independently of p53. Consequently, the greater severity of the TP53-mutant B-CLLs compared with ATM-mutant B-CLLs is consistent with the additive effect of defective apoptotic and elevated survival responses after DNA damage in these tumors. We also show that transcription expression profiles of ATM-deficient, TP53-deficient, and wild-type B-CLLs are indistinguishable before irradiation. Therefore, damage-induced transcriptional fingerprinting can be used to stratify tumors according to their biologic differences and simultaneously identify potential targets for treating refractory tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958068     DOI: 10.1182/blood-2003-04-1161

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

Review 1.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

2.  The impact of SF3B1 mutations in CLL on the DNA-damage response.

Authors:  G D Te Raa; I A M Derks; V Navrkalova; A Skowronska; P D Moerland; J van Laar; C Oldreive; H Monsuur; M Trbusek; J Malcikova; M Lodén; C H Geisler; J Hüllein; A Jethwa; T Zenz; S Pospisilova; T Stankovic; M H J van Oers; A P Kater; E Eldering
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

Review 3.  Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia.

Authors:  Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2005-12-31       Impact factor: 3.201

4.  CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

Authors:  Frank Dicker; Arnon P Kater; Carlos E Prada; Tetsuya Fukuda; Januario E Castro; Guizhen Sun; Jean Y Wang; Thomas J Kipps
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

5.  ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.

Authors:  Anna Guarini; Marilisa Marinelli; Simona Tavolaro; Emanuele Bellacchio; Monia Magliozzi; Sabina Chiaretti; Maria Stefania De Propris; Nadia Peragine; Simona Santangelo; Francesca Paoloni; Mauro Nanni; Ilaria Del Giudice; Francesca Romana Mauro; Isabella Torrente; Robin Foà
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

6.  Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.

Authors:  Angelo Agathanggelou; Victoria J Weston; Tracey Perry; Nicholas J Davies; Anna Skowronska; Daniel T Payne; John S Fossey; Ceri E Oldreive; Wenbin Wei; Guy Pratt; Helen Parry; David Oscier; Steve J Coles; Paul S Hole; Richard L Darley; Michael McMahon; John D Hayes; Paul Moss; Grant S Stewart; A Malcolm R Taylor; Tatjana Stankovic
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

7.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

8.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.

Authors:  Timothy C Greiner; Chiranjib Dasgupta; Vincent V Ho; Dennis D Weisenburger; Lynette M Smith; James C Lynch; Julie M Vose; Kai Fu; James O Armitage; Rita M Braziel; Elias Campo; Jan Delabie; Randy D Gascoyne; Elaine S Jaffe; Hans K Muller-Hermelink; German Ott; Andreas Rosenwald; Louis M Staudt; Michael Y Im; Mazen W Karaman; Brian L Pike; Wing C Chan; Joseph G Hacia
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

9.  Ataxia telangiectasia-mutated dependent DNA damage checkpoint functions regulate gene expression in human fibroblasts.

Authors:  Tong Zhou; Jeff Chou; Yingchun Zhou; Dennis A Simpson; Feng Cao; Pierre R Bushel; Richard S Paules; William K Kaufmann
Journal:  Mol Cancer Res       Date:  2007-08       Impact factor: 5.852

10.  Suppressor of gamma response 1 (SOG1) encodes a putative transcription factor governing multiple responses to DNA damage.

Authors:  Kaoru Yoshiyama; Phillip A Conklin; Neil D Huefner; Anne B Britt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.